White C, Richardson C, Raibstein L
AACN Clin Issues Crit Care Nurs. 1990 Aug;1(2):427-44. doi: 10.4037/15597768-1990-2022.
Dramatic improvement in morbidity and mortality associated with neonatal respiratory failure has evolved over the last 30 years. Favorable survival statistics can be directly related to the institution and refinement of assisted ventilation techniques. Short- and long-term pulmonary complications continue to be of major concern. New ways to support the neonate in respiratory failure are being investigated. Concentrated efforts are being undertaken to find ways to safely and effectively treat these infants while decreasing the morbidity associated with therapy. Two such therapies, both experimental and controversial, which are gaining widespread recognition, are high-frequency ventilation (HFV) and extracorporeal membrane oxygenation (ECMO).
在过去30年里，与新生儿呼吸衰竭相关的发病率和死亡率有了显著改善。良好的生存统计数据可直接归因于辅助通气技术的建立和完善。短期和长期肺部并发症仍然是主要关注点。目前正在研究支持呼吸衰竭新生儿的新方法。人们正在集中精力寻找安全有效的治疗这些婴儿的方法，同时降低与治疗相关的发病率。高频通气（HFV）和体外膜肺氧合（ECMO）是两种正在获得广泛认可的治疗方法，均处于实验阶段且存在争议。
